<DOC>
	<DOCNO>NCT00734487</DOCNO>
	<brief_summary>The purpose study identify whether change age-related macular degeneration ( AMD ) time see spectral domain optical coherence tomography ( SDOCT ) imaging , use predict vision loss advancement AMD people moderate high risk progression .</brief_summary>
	<brief_title>AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study</brief_title>
	<detailed_description>The primary objective study identify whether SDOCT pattern : drusen size , OCT reflectivity within drusen , photoreceptor ( PR ) change drusen , microfoci subretinal fluid ( SRF ) , retinal thicken predictive vision loss , progression drusen , progression photoreceptor loss drusen , development choroidal neovascularization ( CNV ) , development geographic atrophy ( GA ) . The secondary objective study : 1 . To define relationship SDOCT imaging , autofluorescence ( AF ) imaging , color photographic fundus image AREDS 2 patient cross-sectional study baseline data longitudinal study data collect 5 year AREDS 2 study . 2 . To compare extent geographic atrophy SDOCT versus color photograph autofluorescence . 3 . To evaluate whether SDOCT outcome measure differ significantly AREDS 2 patient randomize different oral supplement AREDS2 .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>AMD subject control Men woman age 50 85 year AMD subject Enrollment AREDS 2 trial ; Macular status range large drusen eye large drusen one eye advance AMD ( neovascular AMD geographic atrophy ) fellow eye Ocular medium clear enough allow good fundus photography .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Spectral Domain Optical Coherence Tomography</keyword>
	<keyword>Optical Coherence Tomography</keyword>
	<keyword>AREDS2</keyword>
	<keyword>AMD</keyword>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>Drusen</keyword>
</DOC>